ArabFinance: Minapharm Pharmaceuticals (Minapharm) (MIPH) reported a consolidated net profit after tax excluding minority shareholders’ interest of EGP 352.36 million during the first nine months of 2021, up from EGP 201.13 million in the same period of 2020, according to the consolidated financial statement filed to the Egyptian Exchange.

In the third quarter (Q3) of 2021, Minapharm’s consolidated net profit after tax rose to EGP 102.007 million from EGP 77.64 million in Q3 2020.

The company previously posted a standalone net profit of EGP 225.638 million during the first nine months of 2021, compared to EGP 96.09 million in the same period of 2020.

Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It is in cooperation with several international pharmaceutical companies and it distributes its products within and outside Egypt.